Multiple Sclerosis (MS): is a chronic inflammatory disease of the central nervous system (CNS) that affects the brain and spinal cord. It is characterized by immune-mediated damage to myelin, the protective sheath surrounding nerve fibers. When myelin is damaged, nerve signal transmission between the brain and the rest of the body becomes slowed or disrupted, leading to neurological symptoms such as muscle weakness, numbness, impaired coordination, balance problems, and visual disturbances (Ford, 2020).
MS is considered one of the most common neurological disorders affecting young adults worldwide.
Etiology and Pathophysiology:
The exact cause of MS remains unknown. Current evidence suggests that the disease results from a complex interaction between genetic susceptibility and environmental factors, including viral infections, vitamin D deficiency, and geographic influences (Oh et al., 2018).
Two primary theories have been proposed to explain the disease mechanism:
1. Autoimmune Theory – The immune system mistakenly attacks the body’s own myelin sheath, leading to inflammation and demyelination in the CNS.
2. Infectious Trigger Theory – Certain infections may initiate an abnormal immune response that later targets neural tissue.
Some researchers suggest that MS may represent a post-infectious autoimmune condition, in which an earlier infection triggers long-term immune dysregulation (Confavreux et al., 1991).
Types of Multiple Sclerosis:
1. Clinically Isolated Syndrome (CIS):
CIS refers to a single episode of neurological symptoms caused by inflammation or demyelination in the CNS. Although symptoms may resolve completely, MRI findings may reveal additional silent lesions that support an early diagnosis of MS.
2. Relapsing–Remitting MS (RRMS):
RRMS is the most common form, accounting for approximately 85% of cases at diagnosis. It is characterized by acute relapses (attacks) followed by periods of partial or complete recovery (remission). Disease-modifying therapies can reduce relapse frequency and delay progression.
3. Secondary Progressive MS (SPMS):
SPMS develops in some patients with RRMS over time. In this stage, relapses become less frequent, but neurological disability gradually worsens. Disease progression may occur with or without ongoing relapses.
4. Primary Progressive MS (PPMS):
PPMS is less common and involves gradual worsening of neurological function from disease onset, without clear relapses or remissions.
5. Radiologically Isolated Syndrome (RIS):
RIS refers to MRI findings consistent with MS in individuals without clinical symptoms. Some individuals with RIS may eventually develop clinical MS.
Diagnosis:
Diagnosis of MS relies on clinical evaluation combined with paraclinical investigations to demonstrate dissemination of lesions in time and space.
Magnetic Resonance Imaging (MRI)
MRI is the most important diagnostic tool and detects demyelinating lesions in the brain and spinal cord. Lesions typically appear as hyperintense white matter areas on T2-weighted images (Kaunzner & Gauthier, 2017).
Gadolinium Contrast:
Contrast agents may be used to identify active inflammatory lesions, indicating ongoing disease activity.
Neurological Examination
A neurologist evaluates:
• Reflexes
• Muscle strength
• Sensory function
• Coordination and balance
• Eye movements
Optic neuritis is a common early sign of MS.
Lumbar Puncture
Cerebrospinal fluid (CSF) analysis may reveal oligoclonal bands, indicating abnormal immune activity in the CNS.
Evoked Potential Testing
Evoked potentials measure the speed of nerve signal conduction. Delayed responses may indicate demyelination.
Medical Treatment:
Although there is currently no cure for MS, treatment aims to reduce disease activity, manage relapses, and slow disability progression.
Disease-Modifying Therapies (DMTs)
DMTs target immune system activity to reduce relapse rates and slow disease progression. These medications may be administered as:
• Injectable therapies (e.g., interferon-beta)
• Oral medications
• Intravenous infusions (Tavazzi et al., 2014)
Management of Acute Relapses
High-dose corticosteroids are commonly used to reduce inflammation and accelerate recovery during acute exacerbations.
Symptom Management:
Additional medications may be prescribed to address symptoms such as:
• Spasticity
• Fatigue
• Pain
• Bladder dysfunction
Role of Physical Therapy in Multiple Sclerosis:
Physical therapy plays a crucial role in improving mobility, independence, and quality of life in individuals with MS.
Following a comprehensive assessment of strength, balance, posture, gait, sensory function, and fatigue levels, therapists design individualized rehabilitation programs.
These programs often include:
• Aerobic conditioning
• Strength training
• Balance and coordination exercises
• Functional mobility training
Management of Common Symptoms
Pain:
Managed through therapeutic exercise, stretching, posture correction, manual therapy, and hydrotherapy.
Fatigue:
Addressed using graded aerobic conditioning, pacing strategies, and energy conservation techniques.
Spasticity:
Treated with stretching, range-of-motion exercises, positioning strategies, and occasionally electrical stimulation.
Balance and Coordination Impairments:
Improved through core stabilization exercises, balance training, and gait rehabilitation.
Mobility Limitations:
Functional training and appropriate assistive devices may help maintain independence in daily activities.
Important Clinical Considerations:
Heat Sensitivity
Many individuals with MS experience heat intolerance, where increased body temperature temporarily worsens neurological symptoms. Exercise programs should therefore be conducted in cool environments with adequate hydration and rest breaks.
Energy Conservation
Effective energy management is essential in daily activities. Patients are encouraged to:
• Schedule demanding tasks during high-energy periods
• Take frequent rest breaks
• Maintain proper posture
• Avoid excessive fatigue
Regular moderate exercise 2–3 times per week is generally beneficial.
Psychological Impact:
MS not only affects physical health but also has significant psychological consequences. Studies indicate a higher prevalence of depression, anxiety, and stress among individuals with MS compared with the general population (Boeschoten et al., 2017).
Psychological support, counseling, and mental health interventions are therefore essential components of comprehensive MS care.
References :
Boeschoten, R. E., Braamse, A. M. J., Beekman, A. T. F., Cuijpers, P., van Oppen, P., Dekker, J., & Uitdehaag, B. M. J. (2017). Prevalence of depression and anxiety in multiple sclerosis: A systematic review and meta-analysis. Journal of the Neurological Sciences, 372, 331–341. https://doi.org/10.1016/j.jns.2016.11.067
Confavreux, C., Goudable, B., & Moreau, T. (1991). Etiology of multiple sclerosis. Revue du Praticien, 41(20), 1888–1892.
Ford, H. (2020). Clinical presentation and diagnosis of multiple sclerosis. Clinical Medicine, 20(4), 380–383. https://doi.org/10.7861/clinmed.2020-0292
Kaunzner, U. W., & Gauthier, S. A. (2017). MRI in the assessment and monitoring of multiple sclerosis: An update on best practice. Therapeutic Advances in Neurological Disorders, 10(6), 247–261. https://doi.org/10.1177/1756285617708911
Oh, J., Vidal-Jordana, A., & Montalban, X. (2018). Multiple sclerosis: Clinical aspects. Current Opinion in Neurology, 31(6), 752–759. https://doi.org/10.1097/WCO.0000000000000622
Tavazzi, E., Rovaris, M., & La Mantia, L. (2014). Drug therapy for multiple sclerosis. Canadian